Arbekacin

[{"orgOrder":0,"company":"U.S. Army Medical Research and Development Command","sponsor":"Meiji Seika Pharma | Uniformed Services University of the Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Arbekacin","moa":"antibiotics obtained from Streptomyces kanamyceticus (related to kanamycin)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"U.S. Army Medical Research and Development Command","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"U.S. Army Medical Research and Development Command \/ Meiji Seika Pharma | Uniformed Services University of the Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"U.S. Army Medical Research and Development Command \/ Meiji Seika Pharma | Uniformed Services University of the Health Sciences"},{"orgOrder":0,"company":"Reyon Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"||Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Reyon Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reyon Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Reyon Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kobe University","sponsor":"Japan Medical Association | Nobelpharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Arbekacin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kobe University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kobe University \/ Japan Medical Association | Nobelpharma","highestDevelopmentStatusID":"8","companyTruncated":"Kobe University \/ Japan Medical Association | Nobelpharma"}]